10 clinical trials to watch in the first half of 2023
BioPharma
Source: biopharmadive.com
Page 4 - Andy Plump News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Andy Plump. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Andy Plump Today - Breaking & Trending Today
Takeda to acquire Oral Allosteric TYK2 Inhibitor NDI-034858 from Nimbus Therapeutics
Japan: Takeda has announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment...
Source: medicaldialogues.in
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
13.12.2022 - Takeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases ...
Source: wallstreet-online.de
Takeda's Japan plant reemerges from FDA warning letter as pharma works through pipeline setbacks
Over a year into a stunning FDA warning letter, Takeda has resolved manufacturing problems at home as it gears up to make Novavax’s COVID-19 vaccine for Japan.
Source: fiercepharma.com